Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Open access
Torres-Guzmán, Raquel, Calsina, Bruna, Hermoso, Ana, Baquero, Carmen, Alvarez, Beatriz, Amat, Joaquín, McNulty, Ann M., Gong, Xueqian, Boehnke, Karsten, Du, Jian, de Dios, Alfonso, Beckmann, Richard P., Buchanan, Sean, Lallena, María José·2017·Oncotarget

Abstract

// Raquel Torres-Guzmán 1 , Bruna Calsina 1 , Ana Hermoso 1 , Carmen Baquero 1 , Beatriz Alvarez 1 , Joaquín Amat 1 , Ann M. McNulty 2 , Xueqian Gong 2 , Karsten Boehnke 1 , Jian Du 2 , Alfonso de Dios 3 , Richard P. Beckmann 2 , Sean Buchanan 2 and María José Lallena 1 1 Quantitative Biology, Eli Lilly and Company, Madrid, Spain 2 Oncology Research, Eli Lilly and Company, Indianapolis, Indiana, USA 3 Discovery Chemistry, Eli Lilly and Company, Indianapolis, Indiana, USA Correspondence to: María José Lallena, email: lallena_maria_jose@lilly.com Keywords: abemaciclib, cell cycle, hormone receptor positive breast cancer, senescence, apoptosis Received: October 06, 2016 Accepted: April 24, 2017 Published: May 10, 2017 ABSTRACT Abemaciclib is an ATP-competitive, reversible kinase inhibitor selective for CDK4 and CDK6 that has shown antitumor activity as a single agent in hormone receptor positive (HR+) metastatic breast cancer in clinical trials. Here, we examined the mechanistic effects of abemaciclib treatment using in vitro and in vivo breast cancer models. Treatment of estrogen receptor positive (ER+) breast cancer cells with abemaciclib alone led to a decrease in phosphorylation of Rb, arrest at G1, and a decrease in cell proliferation. Moreover, abemaciclib exposure led to durable inhibition of pRb, TopoIIα expression and DNA synthesis, which were maintained after drug removal. Treatment of ER+ breast cancer cells also led to a senescence response as indicated by accumulation of β-galactosidase, formation of senescence-associated heterochromatin foci, and a decrease in FOXM1 positive cells. Continuous exposure to abemaciclib altered breast cancer cell metabolism and induced apoptosis. In a xenograft model of ER+ breast cancer, abemaciclib monotherapy caused regression of tumor growth. Overall these data indicate that abemaciclib is a CDK4 and CDK6 inhibitor that, as a single agent, blocks breast cancer cell progression, and upon longer treatment can lead to sustained antitumor effects through the induction of senescence, apoptosis, and alteration of cellular metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.17778

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 196

Metadata

Authors
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., de Dios, A., Beckmann, R. P., Buchanan, S., & Lallena, M. J.
Venue
Oncotarget
Published
2017-05-10
Volume
8
Issue
41
Pages
69493-69507
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2612124029
Cited by
196
References
9
FWCI
11.14
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. https://app.cochat.ai/papers/10.18632/oncotarget.17778
The paper
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., de Dios, A., Beckmann, R. P., Buchanan, S., & Lallena, M. J. (2017). Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget. https://doi.org/10.18632/oncotarget.17778

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.